Lasmitidan
Sponsors
Eli Lilly & Co.
Conditions
Migraine
Phase 3
H8H-MC-LAHW: A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with Migraine - PIONEER-PEDS2
CompletedCTIS2023-506724-85-00
Start: 2020-11-19End: 2025-12-04Target: 175Updated: 2025-04-17
H8H-MC-LAHV: Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
CompletedCTIS2023-506253-38-00
Start: 2020-11-09End: 2025-09-30Target: 205Updated: 2025-04-03